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To determine whether kidney function independently relates to endothelial activation and ul-
trasound determined carotid atherosclerosis in black and white Africans with rheumatoid ar-
thritis (RA).
Methods
We calculated the Jelliffe, 5 Cockcroft-Gault equations, Salazar-Corcoran, Modification of
Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) estimated glomerular filtration rate (EGFR) equations in 233 (112 black)
RA patients.
Results
The CKD-EPI eGFR was<90 ml/min/1.73m2 in 49.1% and 30.6% of black and white pa-
tients, respectively (odds ratio (95% confidence interval) = 2.19 (1.28–3.75), p = 0.004).
EGFRs were overall consistently associated with monocyte chemoattractant protein-1 and
angiopoietin 2 concentrations in white patients, and with carotid intima-media thickness and
plaque in black participants. Amongst black patients, plaque prevalence was 36.7% and the
area under the curve (AUC) of the receiver operating characteristic (ROC) curve was not as-
sociated with plaque presence for the MDRD equation (p = 0.3), whereas the respective re-
lationship was significant or borderline significant (p = 0.003 to 0.08) and of similar extent
(p>0.1 for comparisons of AUC (SE)) for the other 8 equations. Based on optimal eGFR cut-
off values with sensitivities and specificities ranging from 42 to 60% and 70 to 91%
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respectively, as determined in ROC curve analysis, a low eGFR increased the odds ratio for
plaque 2.2 to 4.0 fold.
Conclusion
Reduced kidney function is independently associated with atherosclerosis and endothelial
activation in black and white Africans with RA, respectively. CKD is highly prevalent in black
Africans with RA. Apart from the MDRD, eGFR equations are useful in predicting carotid
plaque presence, a coronary heart disease equivalent, amongst black African RA patients.
Introduction
In 1974, Lindner and colleagues [1] reported that atherosclerotic coronary heart disease
(CHD) risk is increased in patients on dialysis. However, dialyzed patients experience increased
mortality due to sudden death and heart failure more frequently than from atherosclerotic
CHD [2]. Endothelial cell dysfunction comprises a central mechanism in the genesis of the dif-
ferent cardiovascular dysfunction aspects in chronic kidney disease (CKD) [2]. Mild renal im-
pairment elevates cardiovascular disease (CVD) risk [3].
Patients with RA sustain an increased risk of CVD [4,5]. Reduced kidney function develop-
ment is enhanced in patients with RA compared to non-RA persons and increases the risk of
cardiovascular events in RA [6,7]. The potential impact of impaired kidney function on athero-
genic mechanisms including endothelial activation and atherosclerosis in RA
requires elucidation.
Both traditional and nontraditional cardiovascular risk factors are associated with prevalent
and incident CVD in RA [8]. Accordingly, currently reported recommendations on CVD risk
stratification in RA include the use of multiple traditional risk factor assessment equations
such as the Framingham score and the Systematic COronary Risk Evaluation score (SCORE)
in combination with consideration of RA characteristics [9]. Nevertheless, up to 85% of white
RA patients considered to be at moderate CVD risk according to the latter approach were re-
ported to have carotid artery plaque [10], which represents a CHD equivalent [11,12]. Impor-
tantly in the present context, we recently found that both traditional cardiovascular risk factors
and RA characteristics were related to atherosclerosis in white but consistently not in black Af-
ricans with RA, this despite a similar atherosclerosis burden amongst the 2 groups [13–15].
Taken together, these findings call for additional easily available and reliable CVD risk markers
in white and even more so in black patients with RA.
Creatinine concentrations are unreliable and creatinine clearance is no longer recom-
mended to estimate kidney function as timed urine collections are cumbersome and prone to
error [16]. The iothalamate, EDTA, diethylene triamine pentaacetic acid or iohexol clearance
most accurately estimate glomerular filtration rate (GFR) [16]. However, performing these in-
vestigations is expensive and complex and not recommended in routine clinical practice [16].
The initially reported Jelliffe estimated glomerular filtration (eGFR) equation in 1973 was a
landmark in the assessment of kidney function [17]. Subsequently, a large series of other equa-
tions calculated from serum creatinine concentrations as well as age and sex with or without
the inclusion of anthropometric measures or race were reported. Amongst these, the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) is most recent and was most exten-
sively validated [18]. Both The Modification of Diet in Renal disease (MDRD) [19] and Chron-
ic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations were also validated in
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non-RA black Africans [20]. To date, only the Cockcroft-Gault (C-G) actual body weight equa-
tion has been validated in a small cohort of white RA patients [21]. The MDRD was reported
to be less accurate than the C-G actual body weight as a measure of creatinine clearance in RA
[22]. A further complicating factor in patients with RA is that they experience excess body fat
for a given body mass index (BMI) and reduced muscle mass [23], which can result in an over-
estimation of kidney function [24–26]. In this regard, the Salazar-Corcoran equation and the
substitution of actual body weight by various other weight measures in the C-G equation can
improve kidney function evaluation in persons with an altered adiposity status [24–26].
In view of these considerations, we evaluated the independent relations of 9 different eGFR
equation values with endothelial activation and atherosclerosis in black and white Africans
with RA. We further aimed at determining the accuracy of eGFR equation results in identifying
patients with carotid plaque or high risk atherosclerosis.
Patients and Methods
Patients
The present study was conducted according to the principles outlined in the Helsinki declara-
tion. The Human Research Ethics Committee (Medical) from the University of the Witwaters-
rand in Johannesburg, South Africa approved the protocol (approval number: M06-07-33).
Participants gave informed, written consent.
This was a two-center based prospective study, comprising consecutive patients. Two hun-
dred and thirty three African patients (112 black and 121 white) that met the 1987 American
College of Rheumatology [27] and 2010 American College of Rheumatology/European League
against Rheumatism (EULAR) criteria for RA [28] were enrolled at the Charlotte Maxeke Jo-
hannesburg (n = 129) and Milpark Hospital (n = 104) in Johannesburg. All invited participants
agreed to participate. Data were missing in fewer than 5% of any of the
recorded characteristics.
Baseline characteristics
Were assessed baseline characteristics using previously reported methods (13–15). Briefly, we
recorded demographic features, and anthropometric characteristics including height, weight
and waist and hip circumference were measured employing standard approaches. The body
mass index (BMI) was calculated and abdominal obesity and fat distribution were estimated by
waist circumference and waist-hip ratio respectively. We recorded disease duration and rheu-
matoid factor status. Anti-cyclic citrullinated peptide antibody concentrations were not consis-
tently evaluated and therefore not included in the analysis. Disease activity was assessed by the
Clinical Disease Activity Index (CDAI) and the Disease Activity Score in 28 joints (DAS28).
Extra-articular manifestations included the current or previously recorded (hospital record re-
view) presence of pericarditis, pleuritis, Felty’s syndrome, cutaneous vasculitis, neuropathy,
scleritis or episcleritis, retinal vasculitis, glomerulonephritis, vasculitis affecting other organs,
amyloidosis, keratoconjunctivitis sicca, xerostomia, Sjogren’s syndrome, pulmonary fibrosis,
bronchiolitis obliterans organizing pneumonia, cervical myelopathy, subcutaneous nodules
and rheumatoid nodules in other locations. C-reactive protein concentrations were determined
using immunoturbidimetric methods. Standard laboratory blood tests of erythrocyte sedimen-
tation rate, lipids and glucose were performed.
We recorded current smoking status and systolic and diastolic blood pressure. Hypertension
was defined as an average systolic blood pressure140 or/and diastolic blood pressure90
mmHg or/and current use of antihypertensive medications. Dyslipidemia was diagnosed when
the atherogenic index, i.e. the cholesterol-HDL cholesterol ratio, was>4. Diabetes was
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identified when glucose lowering agents were used or the fasting plasma glucose was7
mmol/l. The Framingham score was calculated using algorithms [12].
Endothelial activation
Wemeasured early endothelial activation molecule concentrations including those of soluble
E-selectin, vascular cell adhesion molecule-1 (VCAM-1), ICAM-1and monocyte chemoattrac-
tant protein-1 (MCP-1), as well as angiopoietin 2 and using solid-phase sandwich ELISA
(Quantikine1HS, R & D Systems, Inc., Minneapolis, MN, USA). Their lower detection limits
were 0.009 ng/l, 0.6 ng/l, 0.096 ng/l, 5.0 pg/ml and 1.2 pg/ml respectively; their inter- and intra-
assay coefficients of variation were 7.9 and 5.8, 7.0 and 3.1, 5.5 and 4.6, 5.7 and 5.8, and 8.9 and
5.9% respectively.
Atherosclerosis
BAS (see acknowledgement) and AS performed the carotid artery ultrasound measurements in
private and public healthcare patients, respectively. Both operators obtained images of at least
1cm length of the distal common carotid arteries for measurement of the intima-media thick-
ness of the far wall from an optimal angle of incidence defined as the longitudinal angle of ap-
proach where both branches of the internal and external carotid artery are visualized
simultaneously [29] and with high resolution B-mode ultrasound (Image Point, Hewlett Pack-
ard, Andover, MA, USA and SonoCalc IMT, Sonosite Inc, Bothell, Wash, USA used by BAS
and AS, respectively) employing linear array 7.5 MHz probes. The details of the methodology
used by BAS were reported previously [30]. The equipment used by AS involves the application
of a unique semi-automated border detection program that was previously found to provide
highly reproducible results [29]. The intima-media thicknesses in the left and right common
carotid artery were measured and the cIMT was defined as the mean of these. Carotid artery
plaque was defined as a focal structure that encroaches into the arterial lumen of at least 0.5
mm or 50% of the surrounding intima-media thickness value, or demonstrates a thickness of
>1.5 mm as measured from the media-adventitia interface to the intima-lumen interface [31].
Both operators were blinded to the cardiovascular risk profiles of the patients. Repeat ultra-
sound examinations by both operators on 23 patients revealed Spearman correlations between
repeat cIMT measurements of 0.983 and 0.956 for BAS and AS, respectively, and the correla-
tion between measurements made by BAS and AS was 0.926. Both operators identified carotid
artery bulb or/and internal carotid artery plaque in 11 of these 23 patients with full agreement.
Kidney function
Serum creatinine concentrations were measured using the kinetic alkaline picrate method. In
the 129 patients enrolled at the Charlotte Maxeke Johannesburg Academic Hospital, the Advia
Chemistry systems (Siemens) was used with calibration traceable to isotope dilution mass spec-
trometry (IDMS); in the other 104 patients that were recruited at the Milpark Hospital, the
Multiconstituent Calibrator (Architect) was employed which, at that time, was not traceable to
IDMS. The non-IDMS and IDMS traceable values were inter-converted using the following
equations: IDMS serum creatinine = (non-IDMS serum creatinine—0.067)/1.065 and non-
IDMS serum creatinine = IDMS serum creatinine x 1.065 + 0.067 [32]. IDMS serum creatinine
values were used in the CKD-EPI equation and non-IDMS results were employed in the other
equations, as was defined when these equations were initially formulated [17–26]. Table 1 gives
the 9 different eGFR equations [17–26] that were evaluated in the present study. The MDRD
was calculated based on 4 variables [19]. The ethnicity factor as recommended in black
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Americans when calculating the MDRD and CKD-EPI was not applied in the present study as
its use results in an overestimation of kidney function in black Africans living in our region
[20].
Data analysis
Dichotomous variables are expressed as proportions or percentages and continuous variables
as mean (SD) or median (interquartile range) when non-normally distributed. Non-normally
distributed characteristics were also logarithmically transformed prior to their inclusion in
multivariable statistical analysis.
The recorded characteristics were compared between black and white patients using the Stu-
dent t test, Mann-Whitney U or univariate logistic regression analysis as appropriate. To iden-
tify potential confounding variables in subsequent analysis, we assessed the associations of
baseline characteristics with eGFR equations at p0.2 in demographic characteristic adjusted
linear regression models.
The independent relationships of eGFR equations with endothelial activation molecule con-
centrations and cIMT were identified in confounder adjusted linear regression models; inde-
pendent associations between eGFR equations and carotid plaque were evaluated in logistic
regression models.
When consistent independent relations were found between eGFR equations and plaque,
sensitivity versus false positive frequency (1-specificity) for predicting plaque presence with
eGFR levels was analyzed employing receiver operator characteristic (ROC) curves. The pre-
dictive accuracy of eGFR equations was evaluated by the area under the curve (AUC). In this
analysis, we accounted for potential confounding by traditional CVD risk factors and RA
Table 1. Estimated glomerular filtration rate equations.
Jelliffe Men: (98–0.8 x (age—20)) / Scr; women: (98–0.8 x (age—20)) / Scr x 0.9
Cockcroft Gault
ABW




Men: ((140—age) x IBW) / (Scr x 72); women: ((140—age) x IBW) / (Scr x 72) x




Men: ((140—age) x LBW) / (Scr x 72); women: ((140—age) x LBW) / (Scr x 72) x
0.85; with LBW = (9270 x ABW) / (6680 + (216 x BMI)) in men and (9270 x ABW) /
(8780 + (244 x BMI)) in women
Cockcroft Gault
ADBW
Men: ((140—age) x ADBW) / (Scr x 72); women: ((140—age) x ADBW) / (Scr x 72) x
0.85; with ADBW = IBW + (0.4 x (ABW—IBW))
Cockcroft Gault
NBW
Men: (140—age) / Scr; women: (140—age) / Scr x 0.85
Salazar-Corcoran Men: ((137—age x ((0.285 x weight) + (12.1 x height2))) / (51 x Scr); women: ((146—
age x ((0.287 x weight) + (9.74 x height2))) / (60 x Scr)
MDRD Men: 186 x Scr−1.154 x age−0.203; women: 186 x Scr−1.154 x age−0.203 0.742
CKD-EPI Women when Scr 0.7: 144 x (Scr / 0.7)−0.329 x 0.993age and when Scr >0.7: 144 x
(Scr / 0.7)−1.209 x 0.993age; men when Scr 0.9: 141 x (Scr 0.9) −0.411 x 0.993age and
when Scr >0.9: 141 x (Scr / 0.9)−1.209 x 0.993age
Ideal body weight was calculated using the formula by Devine (34) with height measured in centimeters. In
the Salazar-Corcoran equation, weight is expressed in kilogram and height in meter.
Scr = serum creatinine, AWB = actual body weight, IBW = ideal body weight, LBW = lean body Weight,
ADBW = adjusted body weight, NBW = no body weight, MDRD = Modification of Diet in Renal Disease,
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t001
EGFR and Cardiovascular Risk in RA
PLOSONE | DOI:10.1371/journal.pone.0121693 March 25, 2015 5 / 17
characteristics by including as a covariate the Framingham score, this with the application of
the EULAR multiplier of 1.5 in patients with 2 of 3 criteria comprising of (1) a disease duration
>10 years, (2) rheumatoid factor positivity, and (3) the presence of extraarticular manifesta-
tion(s) and thereby giving the modified (m) Framingham score (9). To determine the optimal
cut-off values of eGFR values in predicting plaque presence, we calculated the Youden index
using the following formula: sensitivity + specificity − 1, with the maximum obtained value
corresponding to the optimal cut-off point [33]. Positive and negative predictive values were
determined by applying Bayes’ theorem [34]. We then reassessed the associations of eGFRs
with plaque using the obtained cut-off values in mFramingham score adjusted logistic
regression models.
Statistical computations were made using the GB Stat program (Dynamic Microsystems,
Inc, Silverspring, Maryland, USA) and SPSS software, version 21 (SPSS, Armonk, NY, USA).
Significance was set at p<0.05.
Results
Baseline characteristics
Table 2 gives the baseline characteristics and their comparisons between those obtained in
black and white patients with RA. As compared to whites, black participants were more often
women, experienced a larger adiposity burden, more active and severe RA except for less fre-
quent extraarticular manifestations and more prevalent hypertension and diabetes. The mean
(SD) Framingham score was 6 (7) and 5 (7) in black and white patients, respectively. However,
this characteristic was non-normally distributed with similar median (interquartile range) val-
ues of only 2 (1–5) and 3 (1–6) in the respective groups.
Endothelial activation and atherosclerosis
E-selectin and angiopoietin 2 concentrations were larger and ICAM-1 and MCP-1 levels lower
in black compared to white patients with RA. CIMT values and plaque frequency were similar
in both groups.
Kidney function
Table 2 also gives measures of kidney function in all, black and white patients. As previously re-
ported in non-RA subjects [32], in all patients, IDMS creatinine concentrations were on aver-
age 13% smaller than those of non-IDMS creatinine. The mean (SD) C-G actual body weight
and CKD-EPI eGFR values were similar (91 (28) ml/min versus 93 (17) ml/min/m2, p = 0.2).
Application of the other equations produced consistently lower values (p<0.05 for compari-
sons with CKD-EPI eGFR), as also reported in non-RA subjects [24–26,35].
The non-IDMS and IDMS creatinine concentrations were higher in black compared to
white patients. Kidney function as estimated by the C-G actual body weight equation was simi-
lar in both groups whereas application of each of the other 8 equations revealed reduced values
in black compared to white patients. Taken together, as the C-G actual body weight equation
overestimates kidney function in obese persons [24–26] and black patients experienced excess
adiposity compared to whites (see Table 2), overall, these results indicate that renal function is
impaired in the former compared to the latter group. In this regard also, CKD as defined by a
CKD-EPI eGFR of<90 ml/min/m2 (3,18) was present in 49.1% and 30.6% of black and white
RA patients, respectively; black population origin was associated with CKD (odds ratio (95%
CI) for CKD = 2.19 (1.28–3.75), p = 0.004). Amongst all patients, the eGFR was mildly (60 to
EGFR and Cardiovascular Risk in RA
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Table 2. Recorded characteristics in all 233 and 112 black and 121 white patients with RA.
Demographic characteristics All patients Black White p
Age (years) 57.1 (10.8) 55.7 (10.1) 58.3 (11.4) 0.06
Female sex 82.8 88.4 77.7 0.03
Anthropometry
Body mass index (kg/m2) 27.4 (6.0) 29.3 (6.6) 25.6 (6.6) <0.0001
Body mass index 25 (kg/m2) 58.8 69.6 48.8 0.001
Waist circumference (cm) 91 (13) 93 (13) 89 (13) 0.01
Waist/hip 0.86 (0.80–0.92) 0.85 (0.80–0.90) 0.87 (0.80–0.93) 0.2
Cardiovascular agents
Antihypertensives 46.8 52.7 41.3 0.08
Statins 28.3 19.6 36.4 0.005
Ezetimibe 0.9 0 1.7 . . .
Oral glucose lowering agents 7.7 12.5 3.3 0.01
Insulin 1.7 1.8 1.7 0.9
RA characteristics
Disease duration (years) 13.6 (9.3) 12.9 (9.2) 14.3 (9.4) 0.3
Rheumatoid factor positive 76.7 78.5 75.0 0.5
Clinical Disease Activity Index 7.2 (2.0–13.7) 10.3 (4.0–15.5) 5.1 (0.7–11.7) 0.0001
Disease Activity Score in 28 joints 3.9 (1.5) 4.1 (1.3) 3.6 (1.6) 0.01
Erythrocyte sedimentation rate (mm/hr) 12 (5–27) 21 (9–31) 7 (3–14) <0.0001
C-reactive protein (mg/l) 5.1 (2.1–12.5) 7.0 (4.0–13.8) 3.8 (1.5–10.6) 0.002
Deformed joints (number) 6 (0–15) 8 (3–14) 4 (0–17) 0.03
Extraarticular manifestation(s) 7.7 2.7 12.4 0.01
Synthetic modifying agents
Methotrexate 83.7 90.2 77.7 0.01
Chloroquine 66.1 79.5 53.7 <0.0001
Leflunomide 30.9 22.3 38.8 0.007
Sulphasalazine 18.5 24.1 13.2 0.03
Azathioprine 14.2 16.1 12.4 0.4
Tetracycline 12.0 10.7 13.2 0.6
Cyclophosphamide 3.0 5.4 0.8 0.08
Penicillamine 3.4 4.5 2.5 0.4
Number 2.4 (1.0) 2.5 (1.0) 2.2 (0.9) 0.01
Prednisone use 2.6 1.8 3.3 0.5
Tumor necrosis factor- blockade 3.9 0 7.4 . . .
NSAID 17.6 7.1 27.3 0.0002
Conventional CV risk factors
Hypertension 57.5 70.5 45.5 0.0001
Systolic blood pressure (mmHg) 133 (21) 139 (24) 128 (16) 0.0001
Diastolic blood pressure (mmHg) 82 (12) 86 (14) 79 (9) <0.0001
Total cholesterol (mM) 4.8 (1.0) 4.7 (0.9) 5.0 (1.1) 0.02
HDL cholesterol (mM) 1.5 (1.3–1.9) 1.5 (1.3–1.8) 1.6 (1.3–2.0) 0.07
LDL cholesterol (mM) 2.7 (0.9) 2.6 (0.8) 2.8 (0.9) 0.09
Triglycerides (mM) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 0.6
Cholesterol/HDL cholesterol 3.2 (1.1) 3.3 (1.1) 3.2 (1.0) 0.5
Cholesterol/HDL cholesterol>4 19.7 23.9 16.0 0.1
Non-HDL cholesterol (mM) 3.2 (1.0) 3.1 (0.9) 3.3 (1.0) 0.2
Diabetes 12.5 17.9 7.4 0.002
(Continued)
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89 ml/min/m2 (stage 2 CKD)) and moderately (30 to 59 ml/min/m2 (stage 3 CKD)) reduced in
84 (36.1%) and 8 (3.4%) (4 black and 4 white) RA participants, respectively.
Baseline characteristics associated with kidney function
Associations between baseline characteristics and eGFR equations at p0.2 are shown in S1
Table. Demographic characteristics, adiposity indices, RA characteristics and traditional CVD
risk factors were related to kidney function equations. The Framingham score was significantly
associated with 7 of the eGFR equations and was included in subsequent analysis to account
for potential confounding by traditional CVD risk factors.
Table 2. (Continued)
Demographic characteristics All patients Black White p
Glucose (mM) 4.7 (4.4–5.2) 4.9 (4.5–5.4) 4.7 (4.4–5.1) 0.02
Smoking, current 6.9 3.6 10.0 0.07
Framingham score 2 (1–6) 2 (1–5) 3 (1–6) 0.4
Endothelial activation
Early endothelial activation
E-selectin (ng/ml) 38.6 (18.4) 41.6 (19.8) 35.7 (16.5) 0.02
VCAM-1 (ng/ml) 834 (664–1,048) 835 (696–1,043) 828 (635–1,033) 0.5
ICAM-1 (ng/ml) 277 (214–353) 247 (173–317) 305 (251–385) <0.0001
MCP-1 (pg/ml) 427 (265–683) 351 (223–679) 476 (334–684) 0.009
Angiopoietin 2 (pg/ml) 2,502 (2,044–3,307) 2,681 (2,232–3,566) 2,366 (1,924–3,130) 0.002
Carotid atherosclerosis
Intima-media thickness (mm) 0.709 (0.111) 0.703 (0.090)) 0.715 (0.130) 0.4
Plaque 40.3 36.7 43.8 0.2
Creatinine (mg/dl)
Non IDMS traceable 0.82 (0.72–0.96) 0.87 (0.75–0.89) 0.79 (0.67–0.92) 0.006
IDMS traceable 0.71 (0.61–0.84) 0.76 (0.64–0.86) 0.68 (0.57–0.80) 0.006
EGFR equations
Jelliffe (ml/min) 79 (22) 76 (19) 82 (24) 0.003
C-G ACBW (ml/min) 91 (28) 90 (27) 92 (30) 0.2
C-G IBW (ml/min) 71 (23) 65 (20) 77 (24) <0.0001
C-G ADBW (ml/min) 79 (23) 75 (20) 83 (25) 0.0002
C-G LBW (ml/min) 57 (17) 54 (14) 59 (20) 0.001
C-G NBW (ml/min) 91 (25) 87 (22) 94 (28) 0.0003
Salazar-Corcoran (ml/min) 89 (25) 85 (22) 93 (28) 0.0003
MDRD (ml/min/1.73 m2) 84 (24) 78 (20) 89 (27) 0.0003
CKD-EPI (ml/min/1.73 m2) 93 (17) 90 (17) 95 (17) 0.0005
Results are expressed as mean (SD), median (interquartile range) or proportion as appropriate.
Significant relations are shown in bold.
RA = rheumatoid arthritis, NSAID = non steroidal antiinflammatory agents, VCAM-1 = vascular adhesion molecule-1, ICAM-1 = intercellular adhesion
molecule-1, MCP-1 = monocyte chemoattractant protein-1, IDMS = isotope dilution mass spectrometry, eGFR = estimated glomerular filtration rate,
C-G = Cockcroft-Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body
weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t002
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Kidney function and endothelial activation
Table 3 gives the independent relations of the eGFR equations with the endothelial activation
markers MCP-1 and angiopoietin 2. In all patients, 4 eGFR equations were related to MCP-1
and 5 of them to angiopoietin 2. In stratified analysis, eGFR equations were not associated with
endothelial activation amongst black Africans; by contrast, in whites, all equations were associ-
ated with MCP-1 concentrations and all except the Jelliffe, C-G no body weight and MDRD
equation were related to angiopoietin 2 levels. Kidney function was unrelated to E-selectin,
VCAM-1 and ICAM-1 concentrations (see S2 Table).
Kidney function and atherosclerosis
Table 4 gives the independent relations of eGFR equations with atherosclerosis. In all patients,
the Jelliffe, C-G ideal body weight, C-G no body weight, Salazar-Corcoran and CKD-EPI equa-
tions were associated with cIMT, and the Jelliffe, C-G no body weight and CKD-EPI equations
with plaque. In stratified analysis, all except the MDRD equation were related to cIMT and all
equations were associated with plaque in black patients; a 1 SD increase in eGFR was associated
with an odds ratio of 0.34 (C-G actual body weight) to 0.45 (MDRD) for plaque. By contrast,
no associations between eGFR equations and atherosclerosis were found in whites.
As shown in Fig. 1, to estimate the accuracy of eGFR levels in the independent prediction of
plaque presence amongst black patients with RA, we performed ROC curve analysis with the
inclusion of the mFramingham score as a covariate. The mean (SD) and median (interquartile
Table 3. EGFR formulas and endothelial activation in all, black, white, normal weight and obese patients with RA.
All patients Black patients White patients
MCP-1 Angiopoietin 2 MCP-1 Angiopoietin 2 MCP-1 Angiopoietin 2
EGFR equation β (SE); p β (SE); p β (SE); p β (SE); p β (SE); p β (SE); p
Jelliffe −0.002 (0.001);
0.04
−0.001 (0.001); 0.2 −0.001 (0.002);
0.6
0.001 (0.001); 0.4 −0.003 (0.001); 0.02 −0.001 (0.001); 0.2
C-G ACBW −0.002 (0.001);
0.05




−0.003 (0.001); 0.01 −0.002 (0.001);
0.04
C-G IBW −0.002 (0.001);
0.07






C-G ADBW −0.002 (0.001);
0.06




















C-G NBW −0.002 (0.001);
0.04



















−0.001 (0.001); 0.2 −0.000 (0.002);
0.9
0.000 (0.001); 1.0 −0.002 (0.001); 0.02 −0.001 (0.001); 0.3
CKD-EPI −0.003 (0.001);
0.01








Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI, chloroquine, leflunomide, penicillamine, prednisone and non-steroidal
antiinflammatory agent use adjusted linear regression models.
Significant relations are shown in bold.
EGFR = estimated glomerular filtration rate, RA = rheumatoid arthritis, MCP-1 = monocyte chemoattractant protein-1, C-G = Cockcroft-Gault,
AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body weight,
MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t003
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range) mFramingham scores were 6 (9) and 2 (1–8) in black African patients with RA. The
area under the curve (AUC) of the ROC curve was not associated with plaque presence for the
MDRD (p = 0.3) whereas the respective relation was significant or borderline significant and of
similar extent (p>0.1 for comparisons of AUC (SE)) for the other 8 equations. The AUC of the
ROC curve was consistently not associated with plaque presence for the mFramingham score.
To determine the optimal cut-off values for the eGFR equations in determining plaque pres-
ence we calculated the Youden index [33]. The obtained values and their corresponding sensi-
tivity, specificity, and positive and negative predictive values as determined by applying Bayes’
theorem [34] are given in Table 5. EGFR values below these cut-off levels were significantly or
borderline significantly associated with plaque with odds ratios ranging from 2.22 to 4.00.
In 108 of the black patients with RA, IDMS traceable creatinine concentrations were ob-
tained. As shown in S3 Table in a sensitivity analysis performed amongst these patients, the as-
sociations of eGFR equations with plaque were consistently numerically stronger with lower
odds ratios than in the whole group (Table 4), irrespective of whether conversion of IDMS cre-
atinine to non-IDMS creatinine results was performed (the first 8 equations) or not (the
CKD-EPI equation). This suggests that the use of converted creatinine results in eGFR equa-
tions does not affect their associations with CVD risk in RA.
Table 4. Associations of EGFRwith carotid intima-media thickness and plaque (per 1 SD increase in eGFR) in all, black and white patients with
RA.
All patients Black patients White patients
CIMT plaque CIMT plaque CIMT plaque


































































































Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI, chloroquine, leflunomide, penicillamine, prednisone and non-steroidal
antiinflammatory agent use adjusted linear or logistic regression models for cIMT and plaque, respectively.
Significant relations are shown in bold.
EGFR = estimated glomerular filtration rate, SD = standard deviation, RA = rheumatoid arthritis, cIMT = carotid intima-media thickness, C-G = Cockcroft-
Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body Weight,
MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t004
EGFR and Cardiovascular Risk in RA
PLOSONE | DOI:10.1371/journal.pone.0121693 March 25, 2015 10 / 17
Fig 1. Receiver operator characteristic curves showing the accuracy of the eGFR equations (AUCs shown as dotted lines) in predicting plaque
presence independent of the mFramingham score (AUCs shown as dashed lines). The P values given are for the AUC-plaque associations. The
mFramingham score was consistently unrelated to plaque presence (AUC = 0.596 (P = 0.1) in each analysis). EGFR = estimated glomerular filtration rate;
AUC = area under the curve; C-G = Cockcroft-Gault; MDRD =Modification of Diet in Renal Disease; CKD-EPI = Chronic Kidney Disease Epidemiology
Collaboration.
doi:10.1371/journal.pone.0121693.g001
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Metabolic risk factors and kidney function in black compared to white
patients with RA
In the present study, metabolic risk factors including not only BMI but also hypertension and
diabetes were more adverse in black compared to white patients with RA (Table 2) and, at the
same time, associated with kidney function (S1 Table). Both BMI and 5 of the eGFR equations
as used in the present study contain body weight. Hence, as was previously reported in non-RA
subjects, positive associations between body weight and kidney function as estimated by the re-
spective equations is expected [36]. However, this does not accurately represent a ‘cardio-renal’
relationship [36]. As shown in S4 Table File after adjustment for metabolic risk in multivariable
linear regression models, eGFR equations that did not contain anthropometric measures (Jel-
liffe, C-G no body weight, MDRD and CKD-EPI) no longer differed amongst both groups.
BMI had a strong attenuating effect on the race-eGFR equation relation.
Discussion
Although*80% of cardiovascular disease now occurs in low or middle income countries, data
on cardiovascular risk management mostly originate in developed populations [13–15]. The
present study revealed that reduced kidney function as assessed by previously reported eGFR
equations for use in clinical settings, is independently associated with increased atherosclerosis
in black Africans with RA. EGFR equations comprise the first reported easily and in fact rou-
tinely available cardiovascular risk marker shown to be useful in CVD risk stratification
amongst RA patients from black African ancestry. Indeed, in ROC curve analysis, apart from
the MDRD, eGFR equation results that fell below optimal cutoff values with sensitivities, speci-
ficities and positive and negative predictive values ranging from 42 to 60%, 70 to 91%, 21 to
34% and 72 to 76% respectively, increased the odds ratio for plaque 2.2 to 4 fold. The relatively
high specificities and negative predictive values suggest that African black RA patients with
non-reduction in eGFR are unlikely to have plaque, whereas the low positive predictive values
are expected as the prevalence of plaque was, although clinically relevant, numerically low at
36.7%. Carotid plaque represents very high CVD risk that generally requires the preventive use
Table 5. Optimal cut-off EGFR values in ROC curves with corresponding characteristics and associations with plaque in black patients with RA.
EGFR Cut-off value Sensitivity (%) Specificity (%) PPV (%) NPV (%) OR (95% CI) * p*
Jelliffe 64 45 82 24 72 3.61 (1.43–9.11) 0.007
C-G ACBW 85 60 70 34 75 3.36 (1.46–7.75) 0.004
C-G IBW 54 42 88 22 72 2.22 (0.95–5.21) 0.07
C-G ADBW 68 55 81 29 75 2.72 (1.19–6.20) 0.02
C-G LBW 49 58 79 30 76 3.31 (1.45–7.55) 0.005
C-G NBW 73 45 84 24 72 4.00 (1.57–10.17) 0.004
Salazar-Corcoran 79 55 81 29 75 2.72 (1.19–6.22) 0.02
MDRD 64 35 91 18 70 2.49 (1.00–6.18) 0.05
CKD-EPI 82 42 91 21 73 2.22 (0.95–5.22) 0.07
Significant associations are shown in bold.
EGFR = estimated glomerular filtration rate, ROC = receiver operator characteristic, RA = rheumatoid arthritis, PPV = positive predictive value,
NPV = negative predictive value, OR = odds ratio, CI = confidence interval, C-G = Cockcroft-Gault, AWB = actual body weight, IBW = ideal body weight,
ADBW = adjusted body weight, LBW = lean body weight, NBW = no body weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic
Kidney Disease Epidemiology Collaboration.
*Associations were assessed in modified Framingham score adjusted logistic regression models.
doi:10.1371/journal.pone.0121693.t005
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of CVD drugs in both non-RA and RA subjects [8,11,12,37,38]. The AUC of the ROC curve for
the C-G actual body weight-plaque relations was as large as those recently reported for rheu-
matoid factor and anti-cyclic citrullinated peptide-radiographic progression relation amongst
patients with early RA [39]. Our results are also congruent with our reported finding that
major traditional cardiovascular risk factors as well as previously investigated disease charac-
teristics are not related to atherosclerosis in black Africans with RA, as the mFramingham was
not related to plaque in these patients [13–15].
An independent association of eGFR equation values with the endothelial activation mark-
ers MCP-1 and angiopoietin 2 concentrations was found in white Africans with RA. Increased
production of MCP-1 and angiopoietin 2 was reported and is linked to inflammation and im-
plicated in the enhanced CVD risk amongst non-RA CKD patients [40–42]. Angiopoietin 2
concentrations also predict mortality in CKD [42]. Recently, angiopoietin 2 was shown to im-
pact proliferation and apoptosis of cardiac endothelial cells and promote mesenchymal transi-
tion thereby leading to cardiac fibrosis [41] and capillary rarefaction. These processes increase
the susceptibility to arrhythmias and ischemic injury in CKD [2,41].
The disparities in kidney function-CVD relations amongst black and white Africans with
RA in the present investigation require further exploration. In this regard however, black Afri-
cans experienced markedly reduced kidney function with a 2.2 fold risk of CKD when com-
pared to whites. Kidney function was reported to decrease more rapidly with age in black
persons [43]. The most important causes of CKD are hypertension and diabetes [2,4]. Addi-
tionally, obesity is associated with glomerular hyperfiltration that mediates glomerular sclerosis
[44,45]. This together with the impact of obesity on other CKD risk factors including metabolic
parameters and renin angiotensin system and sympathetic nervous system activation engen-
ders reduced kidney function over time in obese subjects (44,45). In this study, disparities in
kidney function amongst black and white Africans with RA were explained by more adverse
metabolic risk factor profiles in the former group, particularly obesity and to a lesser extent hy-
pertension and diabetes. Interestingly, BMI but not hypertension and diabetes, was recently
also shown to associate with kidney function reduction development in a predominantly white
RA cohort [4]. Compared to the present investigation, kidney function was more impaired in
previous studies that documented its impact on incident cardiovascular events in RA [6,7].
We assessed kidney function using 9 different equations [17–26]. The association of the ob-
tained results with endothelial activation was consistent across these different measures
amongst white RA patients. Overall, the same applied to the relations of the different equations
with atherosclerosis in black patients with RA. Nevertheless, the AUC of the ROC curve for the
MDRD equation was not associated with plaque presence amongst black patients with RA.
Our results suggest that the application of any of the other 8 assessed equations as examined in
the present study is more reliable and therefore preferable to the MDRD equation for CVD risk
stratification amongst black RA patients.
Can a single EGFR equation be recommended in the management of patients with RA? Kid-
ney function evaluation is important for drug dosing [46], CKD staging in delineating renopro-
tective intervention strategies to prevent end stage renal disease [16], and CVD risk
stratification and management [3]. Whereas only the C-G actual body weight was previously
validated in white patients with RA (21), the CKD-EPI equation is currently most recom-
mended in CKD staging in non-RA subjects. The C-G equations have become the standard for
drug dosing. Nevertheless, recent recommendations from the National Kidney Education Pro-
gram suggest that both the C-G and CKD-EPI equations can be used for drug dosing [46]. In
the present investigation, application of the C-G actual body weight and CKD-EPI equations
produced equivalent eGFR values that were further similarly associated with atherosclerosis in
black patients and endothelial activation in whites. Calculation of the CKD-EPI equation does
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not require information on body weight measurements, which is mostly not available to report-
ing laboratories. Taken together, although the CKD-EPI equation awaits validation in patients
with RA, our results suggest that its recommended use in non-RA subjects can be extended to
the RA population. Notably, anthropometric measures are also not include in the C-G no body
weight equation and a recent meta-analysis showed that amongst C-G equations, the C-G no
body weight equation most closely estimates creatinine clearance in non-RA patients [26].
A limitation of the present study is its cross-sectional design, thereby precluding drawing in-
ferences on the direction of causality. Kidney function was defined by estimating equations. A
large number of potential confounders were included in the models on plaque in Table 4.
When we re-assessed the associations of kidney function with plaque using a summary score of
traditional and non-traditional cardiovascular risk factors being the mFramingham score, as
currently recommended for CVD risk stratification amongst patients with RA (9) and as a sin-
gle covariate in the analysis, the results were consistent (Table 5).
Perspectives
Impaired kidney function is frequent and should therefore be routinely ascertained in RA pa-
tients. A C-G ACBW equation result of<85 ml/min, C-G NBW of<73 ml/min or CKD-EPI
of<82 ml/min comprises a useful surrogate marker of high risk subclinical atherosclerosis in
black African patients with RA. This finding can help in determining the need for enhanced
CVD risk stratification by carotid ultrasound [8,11,12] or, intensified risk management with
cardiovascular drugs including statins in black African RA patients who have no access to
cardiovascular imaging.
Conclusions
CKD is twice as prevalent in black compared to white Africans with RA. Reduced kidney func-
tion is independently associated with atherosclerosis and endothelial activation in black and
white Africans with RA, respectively. Apart from the MDRD, eGFR equations are useful in
CVD risk stratification in black African RA patients.
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